Through Diversification Into Horizontal Markets, Singlepoint Is Building Its Portfolio By Acquiring An Interest In Undervalued Subsidiaries, Thereby Providing A Rich, Diversified Holding Base.

CannabisNewsWire Announces Publication Highlighting Investment Opportunities in Cryptocurrency NEW YORK, NY–(Marketwired – Oct 25, 2017) – CannabisNewsWire (“CNW”), a multifaceted financial news and publishing company for the cannabis industry, today announces the publication of an editorial featuring SinglePoint, Inc. ( : SING ), a client of CNW focused on strengthening its position in the marijuana industry through the acquisition of, or investment in, small to mid-sized cannabis companies. The publication, titled, “Bitcoin’s Recent Gains Spell Opportunity for Cryptocurrency Companies,” shines a light on the current demand for alternative investment options. To view the full publication, visit: “SinglePoint has entered a period of rapid development aimed at executing on its bitcoin payments solution. The company’s management team noted that a recently announced new round of funding would play a key role in SinglePoint’s efforts to “move very quickly to develop a cryptocurrency solution and continue acquisitions in the cannabis space.” In early August, SinglePoint confirmed ( ) the swiftness of its development efforts by announcing the commencement of development for its in-house solution enabling consumers to ‘obtain bitcoin at any point of sale.’ While this new payment exchange is expected to be particularly Medical marijuana useful to the maturing cannabis sector, its potential applications could extend well beyond the bounds of marijuana. “As SinglePoint noted in a news release, its new product will be ‘a payment service to make instant bitcoin powered purchases possible when all you have is a credit (or debit) card,’ presenting upside for a wide variety of businesses, most notably in high risk markets.” SinglePoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base. Through its subsidiary company SingleSeed the company is providing products and services to the cannabis industry.

To read more visit

For The Time Being, The Company’s Stock Appears Priced For Perfection.

What the heck is going on here? More than likely, this move has to do with the anticipation of GW Pharmaceuticals’ filing for a new drug application (NDA) with the Food and Drug Administration (FDA) for Epidiolex very soon. Epidiolex is an oral cannabinoid-based medicine that, in phase 3 clinical trials, generated a statistically significant reduction in seizure frequency for patients with two rare types of childhood-onset epilepsy, Dravet syndrome and Lennox-Gastaut syndrome. GW Pharmaceuticals’ management team has suggested that investors expect an NDA filing by mid-2017, which would signal it’s due any time now.  If Epidiolex gets a green light from the FDA, and it’s fortunate enough to expand its label beyond just the two aforementioned rarer types of epilepsy, it could make a run at perhaps $1 billion in peak annual sales. This is why investors are so bullish regarding GW Pharmaceuticals. Still, we’ll need to see if the FDA grants the company a priority review, which would shorten the NDA review period by four months to a six-month process and get Epidiolex to market quickly. Further, an approval is no guarantee for a cannabinoid-based product. Likewise, with the company’s only Marijuana Stocks other approved product (outside the U.S.), Sativex, failing to garner much in the way of sales, there are concerns about GW Pharmaceuticals’ effectiveness in marketing and pricing Epidiolex, if approved. For the time being, the company’s stock appears priced for perfection. Unlike GW Pharmaceuticals, where hope seems to reign supreme, three press releases over the past couple of weeks have been wholly responsible for Aurora Cannabis’ ( NASDAQOTH:ACBFF ) charge higher. In just two weeks, the Canadian medical-cannabis producer and retailer has seen its share price rocket 29% higher.

To read more visit

Its Primary Goal Is To Replace Opioids, Which Can Be Addictive And Even Deadly.

Two years ago, Arena reported positive phase 1b results involving etrasimod for the treatment Medical marijuana of various autoimmune diseases, including ulcerative colitis, which is currently in phase 2 studies. The early stage study demonstrated up to a 69% dose-dependent lowering in lymphocyte count from baseline, which returned to normal within one week after the conclusion of dosing. The press release suggested that this early data was consistent with the efficacy shown in successful phase 2 and 3 studies involving S1P1 modulators in multiple sclerosis, psoriasis, and ulcerative colitis. In other words, etrasimod, though still in early trials, looks promising. Of course, the real buzz involves APD371 , which is an oral Crohn’s disease pain drug that targets the CB2 receptor of the naturally occurring cannabinoid receptor system in our bodies. Targeting CB2 is a smart move for Arena (and other drugmakers, for that matter) since the CB2 receptor has been shown to provide pain relief without the normal psychoactive effects observed with targeting the CB1 receptor. Its primary goal is to replace opioids, which can be addictive and even deadly. Some 20,000 people in the U.S. died from prescription opioid-related overdoses in 2015, compared to zero marijuana-based overdose deaths. A placebo-controlled phase 1b dose-escalating study involving APD371 appeared safe, with only low-grade adverse events observed. Furthermore, all doses tested, even lower doses, were deemed to be more than enough to stimulate the CB2 receptor and achieve the desired biologic effect. Replacing opioid therapies is a lofty goal, but it’s Arena’s biggest hope.

To read more visit

From A Sales Perspective, A Recent Marijuana Business Daily Report Titled Marijuana Business Factbook 2017 Found That U.s.

According to both the 2016 Gallup poll and the more recent CBS News poll, an all-time record percentage of respondents — 60% and 61%, respectively — want to see marijuana legalized across the country. If pollsters focus purely on medical cannabis, favorability toward legalization shoots to somewhere in the neighborhood of 90%, depending on the source of the survey. With such growing acceptance of cannabis, marijuana stock investors fully anticipate that recreational and medical sales will continue to thrive. From a sales perspective, a recent Marijuana Business Daily report titled “Marijuana Business Factbook 2017” found that U.S. sales are expected to grow approximately 30% this year to a range of $5.1 billion to $6.1 billion, with legal recreational and medical sales combined reaching a projected $17 billion by 2021. Between 2016 and 2021 we’re looking at 300% sales growth . Investors would struggle to find more consistent growth elsewhere, which is why they’ve flocked to pot stocks. Hot marijuana stocks that are growing like a weed However, over the two-week period between July 7 and July 21, three marijuana stocks have really stood out from the pack for Marijuana Stocks their impressive percentage or market-cap gains. Let’s have a closer look at which companies have truly been “growing like a weed” recently. In spite of no major news events, the mammoth of all marijuana stocks, GW Pharmaceuticals ( NASDAQ:GWPH ), has seen its share price move higher by nearly 13% over a two-week period. On a valuation basis, we’re talking about $325 million being added in just 10 days’ time. What the heck is going on here?

To read more visit

And With Nearly A Quarter Of Americans Living In Places Where Adult Use Of Marijuana Was Legalized During The Last Election , Places Like California And Colorado Are Prepared To Push Back Against The Federal Government.

“It continues to be a fluid situation,” said Vivien Azer, a managing director and senior research analyst for the cannabis sector at Cowen . Concern over the prosecution of medical cannabis businesses subsided after the recent budget passed by Congress. It included an amendment that prevents the justice department from using funds to go after medical marijuana. But that doesn’t resolve all the uncertainty. “The risk clearly still exists,” Azer said. “I rule out nothing with the Trump administration.” States saw this risk coming, though. And with nearly a quarter of Americans living in places where adult use of marijuana was legalized during the last election , places like California and Colorado are prepared to push back against the federal government. Trump’s name shows up in filings of less than 14% of all companies, but the stakes are much higher for firms that have bet on the federal government taking a hands-off approach to marijuana policy. “There is a material risk that if the Obama era policies regarding cannabis are Medical marijuana not followed, our business could end and investors could lose their total investment in our Company,” wrote The Marijuana Company of America.

To read more visit

Http:// – Run By Gullickson, A Seven-year Veteran In The Industry, Offers Experienced Guidance Through The Licensing Process For Cannabis Dispensaries. Canna Advisors – Canna Advisors is run by Diane and Jay Czarkowski, former owners of a vertically integrated medical cannabis dispensary. Canna Advisors specializes in consulting and licensing across several states. – Run by Gullickson, a seven-year veteran in the industry, offers experienced guidance through the licensing process for cannabis dispensaries. also maintains business planning tools, pro forma tools and other resources to guide your planning. iAnthus Capital Management – An investment firm that raises money as a publicly traded entity on the Canadian markets and directs funding toward U.S.-based cannabis companies, iAnthus Capital represents a creative solution to Marijuana Stocks the dearth in conventional financing available to the legal American cannabis industry. Know of any other resources for aspiring cannabis entrepreneurs that might make a useful addition to our list? Contact the author at with your suggestions. Adam C. Uzialko, a New Jersey native, graduated from Rutgers University in 2014 with a degree in Political Science and Journalism & Media Studies. When he’s not writing, Adam can often be found reading tomes of political philosophy or hiking through the natural landscapes of New Jersey.

To read more visit

Willie Nelson’s Cannabis Products Are About To Hit California

Weed is always on his mind.

At this point, it’s hard to know if Willie Nelson is more legendary for his music or for his love of weed. In truth, it’s probably both. But over the past few years, the aging folk music icon has been capitalizing on his status as a cannabis celebrity to market and sell ‘Willie’s Reserve,’ his signature brand of marijuana. And after successful rollouts in other weed-legal states, Willie Nelson’s cannabis products are about to hit California.Willie Nelson’s Cannabis Products Will Debut In California Next Year

Singer-songwriter Willie Nelson started Willie’s Reserve in 2015. Building on a long career of singing about and advocating for marijuana use, Willie’s Reserve represents “a culmination of [Nelson’s] vision, and his whole life,” according to company spokesman Michael Bowman.

In 2016, Nelson opened shop in Washington, Colorado and Washington. And it wasn’t long until Willie’s Reserve started appearing on dispensary shelves in Oregon and Las Vegas.

Willie Nelson’s cannabis products offer more than just the folk singer’s signature weed strains. Willie’s Reserve products include edibles, vapes and accessories. And more stores are adding Willie’s products all the time.

But Willie’s Reserve, marketed to “music fans, cannabis connoisseurs & lovers of freedom,” is committed to their recreational user base. You won’t find Willie Nelson’s cannabis products in states that have only legalized medical cannabis.

Instead, the company holds off until recreational sales are legal to make its move.

And of course, the largest weed market in the United States, California, will fully legalize the sale of recreational cannabis products starting in January 2018.

Hence, the subtle announcement on the company’s official Instagram page: “California coming soon.”

Willie Nelson’s Cannabis Products, Willies Reserve, Could Make The Singer Millions

Willie Nelson’s Cannabis Products Are About To Hit California

Recreational weed sales continue to shatter records as the industry marches steadily toward its projected $20 billion by 2020 milestone.

In Colorado, for example, recreational sales topped $1 billion in just the first 10 months of 2016. That’s after a 2015 that saw the state sell just under $1 billion worth of cannabis products.

And market projections in California are even more jaw-dropping.

The Golden State voted to legalize recreational cannabis in 2016, with parts of the law allowing everything but the sale of recreational weed taking effect in 2017.

With full legalization, including selling to anyone over 21, about to hit California on January 1, 2018, market analysts are predicting the marijuana industry in California will skyrocket to $5 billion.

Expanding Willie’s Reserve to California means that Willie Nelson’s cannabis products could easily make the singer millions of dollars.

Willie’s stash, of course, already has some serious brand awareness. And for cannabis connoisseurs who value the source of their flower, Nelson partners with independent and local growers to offer customers a top-tier experience.

Willie’s Reserve, like the man himself, is “trailblazing marijuana products celebrating Willies’ love of cannabis and the culture surrounding it.”

So if you’re a Californian who’s fan of Willie, keep an eye out for Willie Nelson’s cannabis products. They go on sale in California this January.

To read more visit:

The Company Lost Nearly $22 Million In Its Fiscal Fourth Quarter Compared To A Loss Of $5 Million In The Prior-year Period.

Despite these soaring sales, though, Canopy Growth stock has fallen around 10% so far in 2017. Granted, that’s relatively insignificant when you consider that the share price is still up over 190% since the beginning of last year. However, investors should know why the stock isn’t growing as much as its marijuana crops and revenue are. One reason is that Canopy Growth’s bottom-line performance doesn’t look as good. The company lost nearly $22 million in its fiscal fourth quarter compared to a loss of $5 million in the prior-year period. One reason behind this bigger loss was Canopy Growth’s acquisitions activity. However, it is also spending a lot more money than in the past on sales, marketing, and administrative functions. In addition, the Canadian government announced in May that it plans to make significant changes to the medical Marijuana Stocks cannabis program . Those changes include authorizing more providers to supply medical marijuana in the country.

To read more visit

The Answer Decides Whether Investors Should Expect Significant  Share Price Gains .

In partnership with rapper Snoop Dogg’s Leafs brand, Canopy Growth is ready to roll out three new strains of marijuana across Canada by the end of the month. That is exciting news for the recreational marijuana user in Canada, but what does it mean for the company’s earnings? The answer decides whether investors should expect significant  share price gains . This company is one of the only producers turning a profit at $427,000 and $1.95 million in the fourth quarter last year and the first quarter, respectively. Aurora Cannabis achieved two major milestones in the past 30 days that one would expect of a young growth stock. Green Rush First, the company’s shares were moved to the Toronto Stock Exchange’s Venture Exchange. This milestone reflects “remarkably rapid operational and commercial progress,” Chief Executive Terry Booth said. Second, the company said this month that it will issue up to $25 million in convertible debt. This offering makes Aurora Cannabis one of the best capitalized companies in the cannabis sector, Booth said.

To read more visit

CBD Water Could Be The Next Big Trend In Cannabis

CBD water promises to bring together the best of what pure water and CBD have to offer.

A handful of cannabis companies are coming up with innovative new ways to tap into the health benefits of cannabidiol (CBD). In particular, CBD-infused water is the latest product to hit the market. Now, CBD water could be the next trend to sweep the cannabis scene.

The Potential of CBD Water

CBD water is exactly what the name implies: CBD-infused water. The combination of pure water and CBD could have some impressive health and medicinal properties.

For starters, water is crucial for good health. In particular, staying hydrated is a key to pretty much every body function, and is important for maintaining your general well-being.

On top of that, researchers are discovering a number of health and medicinal properties associated with CBD.

In general, CBD is often thought of as the non-psychoactive complement to THC. That’s because it helps mellow out and counteract some of the potentially negative effects of THC.

But beyond that, it also produces a range of powerful effects on its own. So far, research has found that CBD can provide treatment for a number of health conditions. As evidence, here’s a quick rundown of what CBD can do:

  • It can be used as an anti-seizure medicine.
  • CBD has anti-inflammatory properties.
  • CBD is a “neuroprotectant.” That makes it an effective way to treat symptoms associated with a variety of neurodegenerative diseases.
  • It can be a powerful pain-reliever.
  • Recent studies suggest that CBD may be an effective anti-tumor agent.
  • CBD also has antipsychotic properties.
  • It can help reduce anxiety.
  • CBD can help those dealing with PTSD.

CBD water brings all these health and medicinal properties together into a discreet, convenient, easy-to-use format.

You can drink it straight. Alternatively, you can add it to other drinks or snacks to turn pretty much anything you want into a CBD-infused edible.

New Innovations in the Cannabis Industry

CBD water could be the next big trend in the cannabis industry. More immediately, it represents the latest innovation to come out of the industry.

So far, there are already a handful of companies to bring CBD water to market. And many of them rely on some new technologies to make it happen.

Making CBD-infused water is actually a lot more complicated than it might at first sound. That’s largely because cannabinoids like THC and CBD don’t naturally bond well with water.

This means that cannabis companies had to come up with another way of making it happen. As a result, many CBD water products rely on “nano technology.”

CBD Living Water, one of a handful of companies now selling CBD water, said the process relies on “quantum physics” to reduce CBD “into tiny particles, one millionth of their size.” From there, the nano-sized CBD particles are encapsulated “in a water cluster.”

The company claims that this process doesn’t just provide a way to infuse water with CBD. According to the company’s website, those tiny particles of CBD are also more readily absorbed by your body. This, the company reports, helps optimize the medical potential of the cannabinoid.

Final Hit: CBD Water Could Be The Next Big Trend In Cannabis

CBD products are becoming a staple in the legal cannabis market. Researchers continue learning more about how this cannabinoid can be used as a health supplement and as a medical treatment.

This expanded body of research will likely fuel an equally explosive growth in the number of CBD products on the market. CBD water is the latest example of this growth.

Given how easy CBD water is to use, dose, and consume, CBD water could very well become the next big trend in cannabis.

To read more visit: